Clorox Needs This Quarter to Prove April's Guidance Cut Was the Bottom

The Clorox Company (NYSE: CLX) reports fiscal Q4 2026 earnings after the close on Monday, August 3, 2026, with analysts expecting a sharp year-over-year decline that will test whether the consumer products giant can stabilize margins amid persistent cost pressures. The consensus estimate of $1.64 per share represents a 42.86% drop from the prior-year quarter, making this one of the most closely watched releases in the household products sector. With the stock trading near its 52-week low and analyst sentiment deteriorating, investors will scrutinize whether management's turnaround efforts are gaining traction or if further downside lies ahead.

Part 1: Earnings Preview

The Clorox Company manufactures and markets consumer and professional products globally, with a portfolio spanning cleaning supplies, disinfectants, and household essentials under brands including Clorox bleach, Pine-Sol, Glad, and Burt's Bees. The company operates through four segments: Health and Wellness, Household, Lifestyle, and International, serving both retail and institutional customers.

Clorox is scheduled to report fiscal Q4 2026 results after the close on Monday, August 3, 2026. Analysts expect earnings of $1.64 per share on revenue of $1.91 billion. The company most recently reported $1.64 per share for fiscal Q3 2026, beating estimates of $1.48 by 10.81%. However, the upcoming quarter faces a difficult comparison: the consensus estimate of $1.64 represents a 42.86% decline from the $2.87 per share reported in the same quarter last year, reflecting the magnitude of margin compression the company has endured.

Three key themes define this earnings story:

Margin Recovery and Cost Management — Investors are laser-focused on whether Clorox can demonstrate meaningful progress in restoring profitability after a year of severe margin pressure. The company has guided fiscal 2026 EPS to a range of $5.45–$5.65, well below the prior year's $7.72, and any signs of stabilization or improvement in gross margins will be critical to rebuilding confidence.

Volume Trends and Pricing Power — With consumer spending under pressure and private-label competition intensifying, the market will scrutinize whether Clorox can maintain pricing without sacrificing volume. Revenue growth has been anemic, and management's ability to balance price realization with market share retention will signal whether the portfolio still commands premium positioning.

Fiscal 2027 Outlook and Turnaround Trajectory — Analysts project a modest 9.24% EPS growth to $6.03 for fiscal 2027, but credibility hinges on management articulating a clear path to sustainable margin expansion. Any guidance that falls short of expectations could trigger further multiple compression, while a confident outlook might stabilize the stock after its steep decline from the 52-week high of $131.86.

Leading analysts remain cautious. The consensus recommendation sits at 2.44 (between Sell and Hold), with 13 Hold ratings and 5 Strong Sells among the 18 analysts covering the stock. The average price target of $96.06 implies minimal upside from current levels, and sentiment has deteriorated over the past month as one analyst downgraded from Strong Buy to Hold. Commentary suggests skepticism about the pace of recovery, with concerns that structural headwinds may persist longer than management has acknowledged.

Part 2: Historical Earnings Performance

Clorox has delivered a mixed earnings track record over the past four quarters, with two beats and two misses that reveal an inconsistent performance pattern. The company posted its strongest surprise in fiscal Q4 2025, beating estimates by 28.12% with $2.87 per share against a $2.24 consensus. However, that exceptional result was followed by a modest 8.97% beat in Q1 2026 ($0.85 vs. $0.78 expected), then a 2.80% miss in Q2 2026 ($1.39 vs. $1.43 expected), before rebounding with a 10.81% beat in the most recent Q3 2026 ($1.64 vs. $1.48 expected).

The pattern suggests volatility in execution rather than a consistent trend. While the company has beaten estimates in three of the past four quarters, the magnitude of surprises has varied widely, and the Q2 miss demonstrates vulnerability when cost pressures or volume weakness intensify. The upcoming quarter faces a particularly challenging comparison, with the consensus $1.64 estimate representing a steep decline from the prior-year $2.87, making it difficult to deliver a meaningful upside surprise without significant operational improvement.

Investors should note that even when Clorox beats estimates, the absolute EPS levels have trended lower year-over-year, reflecting the structural margin compression the business has endured. The ability to exceed expectations in Q3 2026 despite ongoing headwinds was encouraging, but the bar for Q4 remains high given the difficult comparison and the market's demand for evidence of sustained recovery.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Clorox reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

Historical price action around Clorox earnings reveals significant volatility, with an average absolute Day +1 move of 4.20% and a range of 4.87%. The most recent quarter (April 2026) exemplifies this pattern: despite a modest Day 0 gain of 1.76%, the stock plunged 9.67% on Day +1, the largest single-session decline in the dataset. This sharp reversal suggests the market was disappointed by either the results themselves or the forward guidance, despite the company beating EPS estimates.

The data shows no consistent directional bias — Day +1 moves have been split between gains and losses, with notable upside reactions in August 2024 (7.42%) and February 2026 (2.43%), but also severe drops in February 2025 (7.24%) and April 2026 (9.67%). The average Day 0 move of just 1.22% indicates limited anticipatory positioning, while the much larger Day +1 average of 4.20% confirms that the real price discovery occurs after results are digested.

Given the current setup — with the stock near 52-week lows, deteriorating analyst sentiment, and a consensus estimate implying a 42.86% year-over-year decline — investors should prepare for elevated volatility. The options market's expected move of 7.03% is notably higher than the historical Day +1 average of 4.20%, suggesting heightened uncertainty about this particular release.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.03% (±$6.72) through the August 21 expiration, significantly above the historical average Day +1 move of 4.20%. This elevated implied volatility reflects heightened uncertainty around the release, likely driven by the sharp year-over-year earnings decline, deteriorating analyst sentiment, and the stock's proximity to 52-week lows. Traders are positioning for a larger-than-typical reaction, suggesting the market anticipates either a meaningful positive surprise that could stabilize the stock or further disappointment that extends the downtrend.

Part 3: What Analysts Are Saying

Analyst sentiment on Clorox is decidedly bearish, with a consensus rating of 2.44 placing the stock firmly in Sell territory. The current breakdown shows 13 Hold ratings and 5 Strong Sells among 18 analysts, with zero Buy or Strong Buy recommendations. This lopsided distribution reflects deep skepticism about the company's near-term prospects and its ability to reverse margin compression.

Sentiment has deteriorated over the past month, with one analyst downgrading from Strong Buy to Hold, eliminating the sole bullish voice in the coverage universe. The average price target of $96.06 implies virtually no upside from the current price of $95.53, with the range spanning from a low of $77.00 to a high of $118.00. The narrow gap between the current price and the mean target suggests analysts see limited catalysts for appreciation until the company demonstrates sustained operational improvement.

The consensus view appears to be that Clorox is fairly valued at best given its challenged fundamentals, with the risk skewed to the downside if the turnaround takes longer than expected. The clustering of Hold ratings indicates analysts are reluctant to recommend selling at current levels but equally unwilling to endorse the stock as a buy, reflecting a wait-and-see posture ahead of evidence that margins and volume trends are stabilizing.

Part 4: Technical Picture

The Barchart Technical Opinion rates Clorox as a 56% Sell, unchanged from one month ago but improved from 64% Sell one week ago, indicating a modest near-term stabilization after a period of intense selling pressure. The stock remains in a confirmed downtrend, trading at $95.53 well below its 200-day moving average of $104.24, and near its 52-week low of $84.70.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative, though less extreme than in recent weeks
• Medium-term (50% Sell): Consistent sell pressure in the intermediate timeframe reflects ongoing technical deterioration
• Long-term (100% Sell): Strong sell signal confirms the longer-term trend is decisively bearish, with no signs of reversal

Trend Characteristics: The trend is characterized by Soft strength and Average direction, suggesting the downtrend is persistent but not accelerating, with the stock grinding lower rather than collapsing.

The stock is trading below its 5-day ($97.92), 10-day ($96.67), 20-day ($96.33), 100-day ($97.87), and 200-day ($104.24) moving averages, but above its 50-day moving average ($95.44), indicating it has found short-term support near current levels. The convergence of the 50-day average with the current price suggests this level may act as a pivot point heading into earnings.

Key resistance now sits at the 20-day moving average of $96.33, with more substantial overhead at the 100-day average of $97.87. Support is minimal until the 52-week low of $84.70, leaving the stock vulnerable to further downside if earnings disappoint. The overall technical setup is cautionary heading into the release — the stock is oversold and could see a relief rally on any positive surprise, but the weight of the evidence suggests the path of least resistance remains lower until the company demonstrates tangible progress on margin recovery. With all longer-term moving averages in decline and the stock trading near multi-year lows, the technical backdrop offers little cushion for disappointment.